Evidence map›Paper›PMID 35092474›Full record

ArticleEuropean radiology2022

Multi-institutional analysis of outcomes for thermosphere microwave ablation treatment of colorectal liver metastases: the SMAC study.

Francesco De Cobelli, Marco Calandri, Angelo Della Corte, Roberta Sirovich, Carlo Gazzera, Paolo Della Vigna, Guido Bonomo, Gianluca Maria Varano, Daniele Maiettini, Giovanni Mauri and 11 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 2 countries.

Francesco De Cobelli *Department of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.
Marco Calandri *Department of Oncology, University of Torino, Turin, Italy. marco.calandri@unito.it.ORCID http://orcid.org/0000-0002-0297-0700
Angelo Della CorteDepartment of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.
Roberta SirovichDepartment of Mathematics "Giuseppe Peano", University of Torino, Turin, Italy.
Carlo GazzeraRadiology Unit, AOU Città Della Salute E Della Scienza, Turin, Italy.
Paolo Della VignaDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Guido BonomoDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Gianluca Maria VaranoDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Daniele MaiettiniDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Giovanni MauriDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Nicola CamisassiDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Stephanie SteidlerDepartment of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.
Francesca RattiHepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy.
Simone GusminiDepartment of Radiology, IRCCS San Raffaele Hospital, Milan, Italy.
Monica RonzoniUnit of Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Luca AldrighettiSchool of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Bruno C OdisioThe University of Texas, Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX, USA.
Patrizia RaccaColoRectal Cancer Unit, Department of Oncology, AOU Città Della Salute E Della Scienza, Turin, Italy.
Paolo FonioRadiology Unit, AOU Città Della Salute E Della Scienza, Turin, Italy.
Andrea VeltriDepartment of Oncology, University of Torino, Turin, Italy.
Franco OrsiDivisione Di Radiologia Interventistica, Istituto Europeo Di Oncologia, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Vita-Salute San Raffaele University · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITOspedale San Luigi Gonzaga · ITThe University of Texas MD Anderson Cancer Center · USUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOligometastatic colorectal cancer benefits of locoregional treatments but data concerning microwave ablation (MWA) are limited and interactions with systemic therapy are still debated. The aim of this study is to evaluate safety and effectiveness of Thermosphere™ MWA (T-MWA) of colorectal liver metastases (CLM) and factors affecting local tumor progression-free survival (LTPFS).

methodsIn this multi-institutional retrospective study (January 2015-September 2019), patients who underwent T-MWA for CLM were enrolled. Complications according to SIR classification were collected, primary efficacy and LTP were calculated. Analyzed variables included CLM size at diagnosis and at ablation, CLM number, ablation margins, intra-segment progression, chemotherapy before ablation (CBA), variations in size (ΔS

resultsOne hundred thirty-two patients with 213 CLM were evaluated. Complications were reported in 6/150 procedures (4%); no biliary complications occurred. Primary efficacy was achieved in 204/213 CLM (95.7%). LTP occurred in 58/204 CLM (28.4%). Six-, twelve-, and eighteen-month LTPFS were 88.2%, 75.8%, and 69.9%, respectively. At multivariate analysis, CLM size at ablation (p = 0.00045), CLM number (p = 0.046), ablation margin < 5 mm (p = 0.0035), and intra-segment progression (p < 0.0001) were statistically significant for LTPFS. ΔS

conclusionT-MWA is a safe and effective technology with adequate LTPFS rates. Intra-segment progression is significantly linked to LTPFS. CBA does not affect LTPFS. Anticipating ablation before chemotherapy may take the advantages of adequate tumor size with correct ablation margin planning. KEY POINTS: • Thermosphere™-Microwave ablation is a safe and effective treatment for colorectal liver metastases with no registered biliary complications in more than 200 ablations. • Metastases size at time of ablation, intra-segment progression, and minimal ablation margin < 5 mm were found statistically significant for local tumor progression-free survival. • Chemotherapy before ablation modifies kinetics growth of the lesions but deteriorates ablation margins and does not significantly impact local tumor progression-free survival.

Indexed as

Catheter AblationColorectal NeoplasmsLiver NeoplasmsRadiofrequency AblationHumansMargins of ExcisionMicrowavesRetrospective StudiesTreatment OutcomeAblationColorectal neoplasmsMicrowaves

Identifiers

PMID35092474
PMCPMC9123066
OpenAlexW4210505645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.